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Aims The response of the myocardium to an ischaemic insult is regulated by two highly homologous protein kinase C
(PKC) isozymes, d and 1PKC. Here, we determined the spatial and temporal relationships between these two iso-
zymes in the context of ischaemia/reperfusion (I/R) and ischaemic preconditioning (IPC) to better understand their
roles in cardioprotection.
Methods
and results
Using an ex vivo rat model of myocardial infarction, we found that short bouts of ischaemia and reperfusion prior to
the prolonged ischaemic event (IPC) diminished dPKC translocation by 3.8-fold and increased 1PKC accumulation at
mitochondria by 16-fold during reperfusion. In addition, total cellular levels of dPKC decreased by 60+2.7% in
response to IPC, whereas the levels of 1PKC did not signiﬁcantly change. Prolonged ischaemia induced a
48+11% decline in the ATP-dependent proteasomal activity and increased the accumulation of misfolded proteins
during reperfusion by 192+32%; both of these events were completely prevented by IPC. Pharmacological inhi-
bition of the proteasome or selective inhibition of 1PKC during IPC restored dPKC levels at the mitochondria
while decreasing 1PKC levels, resulting in a loss of IPC-induced protection from I/R. Importantly, increased myocar-
dial injury was the result, in part, of restoring a dPKC-mediated I/R pro-apoptotic phenotype by decreasing pro-sur-
vival signalling and increasing cytochrome c release into the cytosol.
Conclusion Taken together, our ﬁndings indicate that IPC prevents I/R injury at reperfusion by protecting ATP-dependent 26S
proteasomal function. This decreases the accumulation of the pro-apoptotic kinase, dPKC, at cardiac mitochondria,
resulting in the accumulation of the pro-survival kinase, 1PKC.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
Myocardial ischaemia and reperfusion (I/R)-induced damage is
associated with both apoptotic and necrotic cell death.
1 We
have shown this to be dependent on translocation of delta
protein kinase C (dPKC) to cardiac mitochondria where it inhibits
mitochondrial function.
2–4 Inhibition of dPKC with the selective
peptide inhibitor, dV1–1, protects the heart from ischaemic
injury.
4,5 Ischaemic preconditioning (IPC) observed in animals and
humans
6–8protects the heart from reperfusion injury by activating
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9–11 preventing apoptosis
12,13 and necrosis
2,4
preserving mitochondrial function,
14,15 and reducing ROS gener-
ation.
16 Many of these effects are afforded, at least in part,
through activation and translocation of 1PKC to cardiac mitochon-
dria,
17–20 resulting in diminished apoptosis and necrosis.
12,21
Interestingly, activation of dPKC is also required for both
opioid
22 and IPC-mediated protection.
23,24 We showed that acti-
vation of dPKC is cardioprotective provided there is sufﬁcient
time allowed for 1PKC activation.
25 Furthermore, 1PKC is acti-
vated by ROS during IPC,
26 whereas dPKC plays a role in ROS gen-
eration.
27 Therefore, although both PKC isozymes play a role in
IPC, the mechanism by which the pro-survival kinase (1PKC) and
the pro-death kinase (dPKC) interact is not known. Here, we
present evidence of a novel mechanism in which the proteasome
alters the ratio between dPKC and 1PKC, thereby regulating myo-
cardial viability following I/R.
2. Methods
2.1 Materials
All antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA).
Lactacystin, LLVY-AMC, epoxomycin, and MG-132 were from Biomol
(Plymouth Meeting, PA). 1V1–2
28 and c1RACK
29 conjugated to TAT
were made by Anaspec, San Jose, CA. This study conforms with the
Guide for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23, revised
1996).
2.2 Isolated perfused rat heart model and
measurement of tissue necrosis
All procedures were carried out as described.
2 All animal protocols
were approved by the Institutional Animal Care and Use Committee
of Stanford University.
2.3 Cellular fractionation and western
blotting
Isolated hearts were homogenized in 210 mM mannitol, 70 mM
sucrose, 1 mM EDTA, and 5 mM MOPS, pH ¼ 7.4. After ﬁltering
through cheesecloth and a 5 min centrifugation at 800 g, the super-
natant was centrifuged (10 000 g; 10 min) to obtain the mitochondrial
pellet and the cytosolic extract (supernatant). This technique provides
a mitochondrial fraction with only traces of sarcolemmal and plasma
membrane contamination.
30 Western blot analysis used polyclonal
1PKC, dPKC, p-Akt, Akt, and cytochrome c antibodies, was normalized
to ANT (mitochondria) and GAPDH (total and cytosolic homogen-
ates) and was expressed as percent control.
2.4 Assay of proteasome activity
Chymotrypsin-like activity of the proteasome was assayed using the
ﬂuorogenic peptide Suc-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin
(25 mM, LLVY-MCA) in a microtiter plate (50 mg protein) with
200 ml of 10 mM MOPS, pH 7.4. Assays were carried out in
the absence and presence of 2.5 mM ATP and 5.0 mM Mg
2þ with
the difference attributed to ATP-dependent proteasome activity. The
rate of ﬂuorescent product formation was measured with excitation
and emission wavelengths of 350 and 440 nm, respectively. In order
to block proteasome activity during the experimental protocol,
2.0 mM lactacystin was perfused during the preconditioning protocol
and the ﬁrst 10 min of reperfusion.
2.5 Slot blot analysis of cellular misfolded
proteins
Heart tissue homogenate (25 mg protein) was normalized and slot
blotted onto PVDF membrane (Millipore, Bedford, MA, USA) and
membranes were washed three times with 0.05% Tween 20, 10 mM
Tris, pH 7.5, 100 mM NaCl (T-TBS) and blocked in T-TBS þ 5%
milk. After 4 h of incubation with an anti-soluble oligomer antibody
(Biosource International, Camarillo, CA), an antibody that recognizes
misfolded proteins,
31 proteins were visualized as in the western blot
analysis. Sample loading was normalized by Ponceau staining.
2.6 Analysis of cellular ATP levels
ATPdeterminationwascarriedoutusingtheMolecularProbesluciferase-
based ATP determination kit (Kit# A22066). In brief, 100 mgo fp r o t e i n
wasincubatedina96-wellplatewith50 mMluciferinand1.25 mg/mLluci-
ferase in a Tris-based 1X reaction buffer containing DTT. ATP was
measuredafter5 minusingaluminometer(560 nmatroomtemperature)
using a standard curve of known ATP concentrations.
2.7 Statistics
Data are represented as the mean+SE, and signiﬁcance was deter-
mined by one-way analysis of variance with a post-hoc Tukey test or
a two-tailed t-test.
3. Results
3.1 IPC diminishes dPKC at the
mitochondria and increases 1PKC
translocation
Since the mitochondria arecritical sites of regulation by d and 1PKC
duringI/R,
2–6,10,16,19–22weﬁrstdeterminedthelevelsofdand1PKC
in this fraction. Thirty minutes of ischaemia and 60 min reperfusion
(I30/R60)( Figure 1A) resulted in accumulation of dPKC (6-fold;
P , 0.001; n ¼ 5) and 1PKC (9-fold; P , 0.05; n ¼ 5) at the mito-
chondria(Figure1B).However,afterIPC,I/R-induceddPKCaccumu-
lation at the mitochondrial fraction was largely prevented, whereas
1PKC translocation increased 2-fold higher than hearts that
werenot preconditioned (P , 0.01; n ¼ 5) (Figure 1B). Interestingly,
IPCresultedinaseven-foldgreaterincreasein1PKCatcardiacmito-
chondria relative to dPKC (Figure 1B). The IPC stimulus alone
(without subsequent I30/R60)( Figure 1C left panel) increased the
levels of both dPKC and 1PKC and caused an 2-fold increase in
their mitochondrial levels relative to normoxic hearts (Figure 1C
right panel; P , 0.05; n ¼ 6).
3.2 Total cellular levels of dPKC
are greatly diminished by IPC
To determine whether the changes in the mitochondrial levels of d
and 1PKC reﬂect changes in the cellular levels of these kinases, we
next determined the levels of both 1PKC and dPKC in total cardiac
extracts. I30/R60 alone did not affect the overall levels of dPKC or
1PKC vs. normoxia (N; n ¼ 4; Figure 2). However, after IPC fol-
lowed by ischaemia, dPKC levels decreased by 33% (vs. N, P ,
0.05; n ¼ 4), whereas 1PKC levels did not. Therefore, the
reduction in dPKC translocation to the mitochondria (Figure 1B)
appears to be associated with diminished protein levels, and this
effect is selective and does not seem to affect 1PKC translocation.
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degradation of dPKC diminished its
translocation to cardiac mitochondria
with a concurrent increase in 1PKC
translocation to this fraction
dPKC has been shown to be degraded by the 26S proteasome.
29
Declines in ATP levels during ischaemia result in the disassembly
of the 26S proteasome into the 20S form.
32 In contrast, IPC
reduces ischaemia-mediated declines in ATP levels.
8,33 We there-
fore determined whether the loss in dPKC levels following IPC
prior to I/R relates to preservation of the 26S proteasome activity.
ATP Mg
2þ-stimulated peptidase activity is a reﬂection of the rela-
tive level of the 26S proteasome. Ischaemia induced a 45% decline
in ATP-dependent proteasomal activity (Figure 3B) that was associ-
ated with an 3-fold increase in the accumulation of misfolded
proteins during reperfusion (Figure 3C). IPC prevented the
Figure 2 Diminished mitochondrial levels of dPKC following
IPC are due to decreased cellular levels of the isozyme. Hearts
were hung in Langendorff mode and treated with the listed per-
fusion protocols in Figure 1. Hearts were then removed, and
homogenized, and the total homogenate was subjected to
western blot analysis with antibodies against the proteins listed
in the ﬁgure. Values were normalized to glyceraldehyde phos-
phate dehydrogenase (GAPDH), a cytosolic protein, and
expressed as %N. I30R60 had no signiﬁcant effect on total levels
of either dPKC or 1PKC. However, IPC before the global ischae-
mic event decreased the overall levels of dPKC by 80%
(P , 0.05 vs. N), but not 1PKC levels. *P , 0.05 vs. Normoxia
and ‡P , 0.05 vs. I30R60. Cellular dPKC and 1PKC levels were
analysed by one-way analysis of variance with a post-hoc Tukey
test.
Figure 1 Ischaemic preconditioning decreases dPKC and
increases 1PKC levels at cardiac mitochondria during reperfusion.
(A) Hearts were hung in Langendorff mode and treated with the
listed perfusion protocols. Hearts were then removed, homogen-
ized, fractionated, and the mitochondrial fraction was subjected
to western blot analysis with antibodies against the proteins
listed in the ﬁgure. Values were normalized to adenine nucleotide
translocase (ANT), a mitochondrial marker, and expressed as%
of normoxia (N) control. (B) Western blot analysis of mitochon-
drial protein showing that 30 min of ischaemia followed by 60 min
of reperfusion (I30R60) resulted in translocation of dPKC to mito-
chondria (six-folds increase; P , 0.05 vs. N), which was blocked
when hearts were preconditioned (IPC) before the global ischae-
mic event (P , 0.05 vs. I30R60). Likewise, 1PKC association with
cardiac mitochondria increased 7-folds during I30R60
(P , 0.05 vs. N), but in contrast to dPKC, IPC prior to I/R
further increased translocation of 1PKC to 16-folds over the
levels seen in normoxic hearts (P , 0.05 vs. N and I30R60). (C)
Western blot analyses showing that the IPC stimulus alone
(without I30R60) signiﬁcantly increased translocation of dPKC
(P , 0.05 vs. N) and 1PKC translocation (P , 0.05 vs. N) to
the mitochondria. *P , 0.05 vs. N, ‡P , 0.05 vs. I30R60) Translo-
cation of dPKC and 1PKC to the mitochondria were analysed by
one-way analysis of variance with a post-hoc Tukey test. Mito-
chondrial PKC levels were analysed by Student’s t-test.
Ischaemic preconditioning and proteasomal regulation of dPKC 387Figure 3 Effect of preconditioning on ischaemia-induced loss in ATP-dependent proteasome activity. (A) Cytosolic extracts were prepared
from hearts exposed to 70 min of normoxic perfusion (N), 30 min of ischaemia (I30), or three cycles of preconditioning (5 min ischaemia and
5 min reperfusion) followed by 30 min of ischaemia (I30 þ IPC) in the absence or presence of the proteasome inhibitor lactacystin or the
speciﬁc 1PKC inhibitor 1V1–2. Chymotrypsin-like activity of the proteasome present in the cytoplasmic milieu was evaluated and the speciﬁc
inhibitor MG-132 (20 mM) was utilized to ensure that measured activities were due to the proteasome (data not shown). The presence of
unfolded proteins was evaluated using the slot blot technique with an anti-soluble oligomer antibody. Values representing ATP-dependent pro-
teasome activity and misfolded proteins are presented as a percent of values obtained with samples from hearts exposed to 60 min of normoxic
perfusion (N). Values represent the mean+standard deviation (n ¼ 4). (B) Ischaemia resulted in a 50% decline in ATP-dependent proteasome
activity (P , 0.05 vs. N), which was completely reversed by IPC (P , 0.05 vs. I30). The proteasome inhibitor, lactacystin (2 mM) and the speciﬁc
1PKC inhibitor (1mM 1V1–2) both signiﬁcantly decreased the activity of the proteasome (P , 0.05 vs. I30R60 þ IPC; n ¼ 4). (C)I 30R60 resulted in
an 3-fold increase in misfolded proteins which was prevented by IPC (P , 0.05; n ¼ 4). Treatment of hearts with lactacystin or 1V1–2blocked
the effect of IPC and increased the accumulation of misfolded proteins. (D) IPC elevated ATP levels by 3.5-fold in hearts that had undergone
I30R60, and 1V1–2blocked these effects. (E) Treatment with the 1PKC activator (c1RACK) protected the proteasome from ischaemia-mediated
inhibition (P , 0.05 vs. I30). *P , 0.05 vs. Normoxia,
þP ¼ 0.05 vs. I30R60,§ P , 0.05 vs. I30,‡ P , 0.05 vs. IPC þ I30,† P , 0.05 vs. IPC þ I30R60;
Misfolded protein accumulation and proteasome activity were analysed by one-way analysis of variance with a post-hoc Tukey test. Figure 3D,
proteasome activity was analysed by Student’s t-test.
E.N. Churchill et al. 388Figure 4 Inhibition of the proteasome restores dPKC cellular and mitochondrial levels in IPC hearts with a resultant decrease in 1PKC levels.
(A) Hearts were hung in Langendorff mode and treated with the above-mentioned perfusion protocols. Hearts were then removed, homogen-
ized, and the total homogenate and mitochondrial fractions were subjected to western blot analysis with antibodies against the proteins listed in
the ﬁgure. Values were normalized to GAPDH (total homogenate) or ANT (mitochondrial fraction) and expressed as% I30R60. IPC before
prolonged ischaemia reduced total levels of dPKC by 80% (P , 0.05 vs. I30R60). Inhibition of the proteasome with 2 mM lactacystin
blocked dPKC degradation (P , 0.05 vs. I30R60 þ IPC). Similar to Figure 2, IPC before prolonged ischaemia did not signiﬁcantly change
overall levels of 1PKC. However, inhibition of the proteasome increased 1PKC levels by 2-folds (P , 0.05 vs. I30R60). Inhibition of 1PKC
activity with 1V1–2 did not signiﬁcantly change the overall levels of either d or 1PKC isozymes (data not shown). (B)A si nFigure 2, IPC
before I30R60 decreased levels of dPKC at mitochondria by 60% (P , 0.05 vs. I30R60). This was completely prevented in hearts treated
with 2 mM lactacystin and 1 mM 1V1–2 (P , 0.05 vs. I30R60 þ IPC). (C) Although dPKC mitochondrial levels were restored, 1PKC levels
were diminished by 40% relative to I30R60 and by 60% relative to I30R60 þ IPC (P , 0.05). Hearts that were treated with 1 mM of a peptide
inhibitor of 1PKC (1V1–2) during the IPC protocol showed a signiﬁcant decrease in 1PKC mitochondrial levels (P , 0.05 vs. I30R60 þ IPC).
*P , 0.05 vs. I30R60,‡ P , 0.05 vs. IPC I30R60. Cellular and mitochondrial PKC levels were analysed by the one-way analysis of variance with
a post-hoc testing by Tukey.
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the levels of misfolded proteins (Figure 3B and C; P , 0.05;
n ¼ 4). Furthermore, ATP levels correlated with proteasomal
activity; ATP levels diminished during ischaemia/reperfusion and
IPC signiﬁcantly prevented this decline (Figure 3D).
To determine if IPC increases proteasomal degradation of
dPKC, we perfused the proteasome inhibitor, lactacystin (2 mM),
during IPC and the ﬁrst 10 min of reperfusion (Figure 3A). Lactacys-
tin signiﬁcantly blocked the activity of the proteasome (75%; P ,
0.01; n ¼ 4; Figure 3B) and increased the levels of misfolded pro-
teins by 7-fold (Figure 3C). In agreement with our ﬁndings in
Figure 2, IPC reduced post-reperfusion cellular levels of dPKC by
80% (P , 0.01; n ¼ 4; Figure 4A). However, inhibition of the
proteasome with lactacystin prevented the loss of dPKC after
IPC and I30R60 (Figure 4A). Although lactacystin treatment did not
affect the levels of 1PKC relative to IPC, the ratio of 1PKC to
dPKC decreased due to elevated levels of dPKC.
Since lactacystin-mediated inhibition of the proteasome during
IPC prevented dPKC degradation, it may promote translocation
of dPKC to cardiac mitochondria. Indeed, lactacystin treatment
completely blocked IPC-induced reductions in dPKC levels, restor-
ing mitochondrial dPKC to levels obtained after I30/R60 alone
(Figure 4B). Interestingly, in contrast to the effects of proteasome
inhibition on total 1PKC levels, mitochondrial levels of 1PKC
were reduced by 50% in the presence of lactacystin (Figure 4C).
These data suggest that IPC inversely affects the ratios of these
Figure 5 Inhibition of dPKC degradation restores the apoptotic phenotype seen during reperfusion. Hearts were hung in Langendorff mode
and treated with the listed perfusion protocols. Hearts were then removed, homogenized, fractionated, and the cytosolic homogenate was
subjected to western blot analysis with antibodies against the proteins listed in the ﬁgure. Values were normalized to GAPDH and expressed
as% I30R60.( A) IPC before prolonged ischaemia signiﬁcantly decreased cytochrome c release into the cytosol (P , 0.05 vs. I30R60). Inhibition of
the proteasome with 2 mM lactacystin restored cytochrome c release to levels seen during I30R60 (P , 0.05 vs. I30R60 þ IPC). (B) Ischaemia
alone and perfusion with lactacystin or 1V1–2 alone did not result in signiﬁcant release of cytochrome c into the cytosol. Additionally, as evi-
denced by a lack of mitochondrial VDAC in the cytosolic fraction, there was little contamination from mitochondrial cytochrome c in this frac-
tion. Enolase was used as a cytosolic loading control. (C) IPC before prolonged ischaemia also increased phosphorylation of the pro-survival
kinase, Akt, by 3-fold (P , 0.05 vs. I30R60). Inhibition of the proteasome with 2 mM lactacystin decreased phosphorylation back to I30R60 levels
(P , 0.05 vs. I30R60 þ IPC). *P , 0.05 vs. I30R60,‡ P , 0.05 vs. IPC I30R60. Cytosolic cytochrome c levels and p-Akt were analysed by one-way
analysis of variance with a post-hoc Tukey test.
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through the regulation of proteasome activity. Additionally, lacta-
cystin abolished IPC-mediated protection of ATP levels following
ischaemia/reperfusion (Figure 3D).
We determined whether 1PKC indirectly downregulates dPKC
by protecting proteasomal function during IPC. To this end, we
perfused the speciﬁc 1PKC inhibitor, 1V1–2
34 (Figure 3A) and
found an 70% inhibition of proteasomal activity, an effect that
was similar to that obtained by lactacystin (Figure 3B), and resulted
in a corresponding increase in cellular misfolded proteins
(Figure 3C). Similar to lactacystin, 1V1–2 treatment signiﬁcantly
decreased 1PKC levels at cardiac mitochondria (71% vs. IPC),
and restored dPKC levels in this fraction (P , 0.05; n ¼ 7)
(Figure 4B and C). Perfusion with a speciﬁc 1PKC activator,
c1RACK, before ischaemia mimicked the IPC-mediated protective
effect on proteasomal activity and prevented the loss in proteaso-
mal activity seen during I/R (Figure 3E). This is likely an indirect
effect, since 1PKC was not found to associate with the proteasome
following c1RACK treatment (data not shown).
3.4 Inhibition of the proteasome prevents
Akt activation and increases release of
cytochrome c during IPC
IPC activates the pro-survival kinases, Akt, and ERK1/2 and blocks
cytochrome c release during reperfusion.
10,15,35 In contrast, dPKC
decreases Akt activation and increases cytochrome c release
during I/R.
2 Here we found that IPC signiﬁcantly blocked I30/R60
mediated release of mitochondrial cytochrome c into the cytosol
(60%; P , 0.05; n ¼ 4) (Figure 5A) and inhibition of the proteasome
with lactacystin restored cytochrome c release to the levels seen
during I30/R60 (P , 0.05). Treatment of non-ischaemic hearts
with either lactacystin or 1V1–2 did not cause signiﬁcant release
of cytochrome c into the cytosol (Figure 5B). Additionally, IPC sig-
niﬁcantly increased the phosphorylation of the pro-survival kinase,
Akt, over I30/R60 levels (300%), and this was abolished by lactacys-
tin treatment (Figure 5C). Li et al. showed that activation of dPKC
reduces Akt phosphorylation whereas inhibition of dPKC
increased Akt phosphorylation. They suggested that
dPKC-mediated inhibition of Akt proceeds through increased
association of protein phosphatase 2a.
36 Neither IPC nor lactacys-
tin treatments signiﬁcantly changed the phosphorylation levels of
ERK-1/2 (not shown), consistent with the ﬁndings of other
studies.
37,38
3.5 Inhibition of the proteasome during
IPC increases tissue injury
Since pharmacological inhibition of the proteasome during IPC
restored the apoptotic phenotype, we determined if tissue injury
is altered by proteasome inhibition. As reported, IPC decreased
both creatine phosphokinase (CPK) release and tetrazolium tetra-
chloride (TTC) staining of the myocardium by 70 and 60%,
respectively (Figure 6A and B) and Lactacystin reversed the beneﬁts
of IPC-mediated protection. As we found before in isolated myo-
cytes,
28 in addition to the effects of 1V1–2on proteasomal function
and dPKC translocation, inhibition of 1PKC also completely
reversed the protective effects of IPC on the myocardium
(Figure 6A and B). Finally, to conﬁrm the effects of lactacystin, we
utilized another highly selective inhibitor of the proteasome, epox-
omicin. Similar to lactacystin, inhibition of the proteasome with
epoxomicin (2 mM) abolished the cardioprotective effects of IPC
(data not shown).
4. Discussion
Our data suggest that IPC-induced decreases in mitochondrial
dPKC levels are due to decreased total levels of dPKC. We also
show that IPC prevents ischaemia-mediated declines in the 26S
ATP-dependant proteasomal activity and that this is associated
with diminished accumulation of cellular misfolded proteins.
Ischaemia-mediated declines in forebrain ATP levels promote dis-
sociation of the 26S proteasome (the form responsible for dPKC
degradation
29) to the 20S proteasome.
32 During I/R, (in the
absence of preconditioning) the signiﬁcant decrease in ATP-
dependent proteasomal activity is therefore likely due to
decreased ATP levels within the cells. Indeed, as has been
shown before,
4,39 and here in an ex vivo model of ischaemia/reper-
fusion, ATP levels signiﬁcantly declined during ischaemia/reperfu-
sion and IPC signiﬁcantly prevented this decline (Figure 3D).
Alternatively, modiﬁcations by lipid peroxidation products and
accumulation of oxidized proteins during I/R may also act as
inhibitors of proteasomal function.
40 Inhibition of the proteasome
with lactacystin or epoxomicin blocked the protective effects of
IPC. Additionally, lactacystin treatment elevated dPKC cellular
and mitochondrial levels, and promoted cytochrome c release.
dPKC is ubiquitinated within 30 min of activation
41 and direct inhi-
bition of the 26S proteasome with Bortezomib, a highly selective
proteasome inhibitor currently in clinical use for the treatment of
haematological cancers, increases mitochondrial ROS generation,
cytochrome c release, and apoptosis associated with mitochon-
drial accumulation of dPKC.
29,42 We suggest that since IPC and
1PKC activation slow ATP depletion during prolonged ischae-
mia
8,43 and dPKC is likely activated by the IPC stimulus
(Figure 1C)
3 the 26S proteasomal activity is maintained leading
to the degradation of pro-apoptotic and pro-necrotic, dPKC,
2,4
thereby conferring cardiac protection. Although the most likely
explanation for the decrease in dPKC levels in the mitochondria
is a decrease in total level of this isozyme in the cells (due to
its increased degradation by the proteasome), we cannot
exclude the possibility that decreased afﬁnity of the binding site
for dPKC in the mitochondria and post-translational modiﬁcations
of the enzyme or its binding proteins also contribute to dPKC
declined levels and therefore activity in the mitochondria. We
have previously shown that accumulation of dPKC at cardiac mito-
chondria increases PDH phosphorylation and the inhibitor dV1–1
prevents this.
3 Additionally, we have shown that 1PKC is able to
activate ALDH2 in hearts in the same in vivo model of I/R.
44
Therefore, we have already provided direct evidence in this
model of I/R that increased levels of PKC isozymes in the mito-
chondrial fraction are associated with increased phosphorylation
of target substrates and hence reﬂect increased catalytic activity
of these isozymes.
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1PKC accumulation at cardiac mitochondria is also likely to confer
protection. 1PKC translocates to mitochondria,
16,19–22 where it pre-
vents opening of the mitochondrial permeability transition pore,
19,45
opens kATP channels,
9 forms signalling complexes with MAPK,
9
retards the reduction in cellular ATP levels,
46 interacts with the elec-
tron transport chain,
47 and augments mitochondrial function
39 all of
which contribute to cardioprotection. Since the relative level of
1PKC at the mitochondria during reperfusion in the absence of the
IPC stimulus is similar to dPKC levels, 1PKC-mediated cardioprotec-
tion may be masked by the pro-apoptotic and pro-necrotic effects
of dPKC during reperfusion. Administration of the 1PKC activator,
c1RACK, prior to ischaemia, which mimics IPC and protects mito-
chondrial function
39 prevented ischaemia-mediated declines in pro-
teasome activity. Although recent studies suggest that kinases may
regulate proteasome function directly,
48 we did not ﬁnd any physical
association between 1PKC and the proteasome.
In summary, activated dPKC has two potential fates that appear
to depend on the metabolic state of the cell. If mitochondrial func-
tion, cellular energy status, and the integrity of the 26S proteasome
are maintained, dPKC is efﬁciently degraded. In contrast, if mito-
chondrial function and ATP production are compromised, the
ATP-dependent 26S proteasome activity is diminished, resulting
in increased levels of activated dPKC at the mitochondria, where
it participates in the induction of cell death. The proteasome can
therefore be viewed as a sensor of cellular viability, determining
the ratio of pro-apoptotic dPKC and pro-survival 1PKC at the
mitochondria and thus the ultimate fate of the cell. We propose
the following mechanism. The decrease in ATP levels seen
during I/R (Figure 3D) and increased generation of reactive
oxygen species, will diminish 26S proteasome activity.
40 dPKC is
activated by ROS
4 and also during the early stages of reperfusion,
resulting in its accumulation at cardiac mitochondria (Figure 1).
3
Because the activity of the proteasome is diminished (Figure 3),
dPKC is not degraded, favouring its accumulation at cardiac mito-
chondria (Figure 4), where it triggers pro-apoptotic cytochrome c
release and inactivation of Akt (Figure 5), leading to tissue injury
(Figure 6). In contrast, IPC is associated with a small burst of mito-
chondrial ROS during the trigger phase of IPC, which decreases
ROS generation during the effector phase
49 and may also act as
a stimulus for dPKC activation (Figure 1C). Diminished ROS gener-
ation and maintenance of cellular ATP levels (Figure 3D) result in
protection of proteasomal function,
50 which leads to degradation
of dPKC (Figure 4A). Since both 1PKC and dPKC accumulate at
the mitochondria during I30R60 (Figure 1B) and since 1PKC is not
degraded during I30R60 (Figure 2A), degradation of dPKC during
IPC tips the balance towards the accumulation of the pro-survival
kinase, 1PKC, at cardiac mitochondria, thus protecting mitochon-
drial function and proteasomal activity thereby diminishing I/
R-mediated tissue injury.
Conﬂict of interest: D.M.-R. is the founder of KAI Pharmaceuti-
cals. However, none of the work described in the study is based on
or supported by the company.
Figure 6 Inhibition of the proteasome reverses the IPC-
mediated protective effects on tissue injury. Hearts were hung
in Langendorff mode and treated with the listed perfusion proto-
cols. Tissue injury was determined by measuring the release of
CPK into the cardiac efﬂuent (total CPK units). Following
removal, hearts were sliced and stained with TTC to differentiate
between necrotic (stained white) and viable (stained red) tissue
(% infarct). (A,B) Hearts subjected to I30R60 showed an increase
in both CPK release and myocardial infarction and both were
blocked by IPC (reductions of 60% for CPK release and
40% for infarction, respectively). Perfusion of 2 mM lactacystin
during the IPC protocol and for the ﬁrst 10 min of reperfusion
reversed this effect resulting in signiﬁcantly higher levels of CPK
release (P , 0.05 vs. I30R60 þ IPC) and myocardial infarction
(P , 0.05 vs. I30R60 þ IPC). Similar to proteasome inhibition,
1PKC inhibition (1 mM 1V1–2) also signiﬁcantly increased both
CPK release (P , 0.05 vs. I30R60 þ IPC) and myocardial infarction
(P , 0.05 vs. I30R60 þ IPC). *P , 0.05 vs. I30R60,‡ P , 0.05 vs. IPC
I30R60. Total CPK and% infarcted area were analysed by the
one-way analysis of variance with a post-hoc Tukey test.
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